Venture Capital

A major state investment at Oklahoma State University is set to transform the local food industry, promising safer, fresher products and economic growth.

As the Milano Cortina 2026 Games close, a look at how specialized online academies are revolutionizing training for elite student-athletes.

Thermon Group's $2.2 billion sale to CECO Environmental faces legal scrutiny, leaving shareholders to question if the offer is fair amid record profits.

With a massive Series A, Alveus Therapeutics is advancing novel drugs aiming for more durable and higher-quality weight loss than current blockbusters.

Dr. Frank Smith joins XenoSTART to lead its preclinical unit, aiming to leverage its vast patient-derived model library to speed up oncology drug development.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

NorthX Biologics and Demeetra have partnered to offer a streamlined, royalty-free path from gene to GMP, tackling key bottlenecks for biotech startups.

Leaving the volatile crypto world behind, Cipher Digital is raising billions to build massive data centers for tech giants like AWS and Google.

Larimar Therapeutics' nomlabofusp receives Breakthrough Therapy Designation, paving an accelerated path for a potential disease-modifying treatment.

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

Blueprint Capital Advisors' new list of 'Active Icons' honors industry giants not just for wealth, but for their commitment to shaping a more inclusive future.

With $1.2M in new funding, Validfor is unleashing agentic AI to tackle pharma's billion-dollar compliance problem and slash validation times.

A new screen protector promises glasses-free 3D on your iPhone. Can MOPIC succeed where tech giants have repeatedly failed?

Avacta's pre|CISION therapy shows faster, more potent, and more selective tumor targeting than Enhertu in an AI-driven study, paving the way for 2026 trials.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

A new platform is treating residential property management like a tech problem, using centralization and automation to reshape a fragmented industry.

A new JBF report reveals how independent restaurants are battling costs, tech, and expectations with surprising optimism and strategic shifts.

A top legal award for David Wittmann reveals his crucial role in guiding Massachusetts' tech startups and his deep commitment to community service.

A former Regeneron exec who built a blockbuster drug joins a medtech startup, signaling a major push to disrupt the multi-billion dollar chemo-port market.